VivoSeq
Infectious Disease

Quadrivalent HPV Vaccine

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Quadrivalent HPV Vaccine is an early-stage landscape with 0 programs across 2 companies. The most active players are Shanghai Bovax Biotechnology Co., Ltd., Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shanghai Bovax Biotechnology Co., Ltd.

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed3 · 50%
Recruiting1 · 17%
Not yet recruiting1 · 17%
Unknown status1 · 17%

Clinical Trials

Trial Activity

6 trials

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Recruiting·SShanghai Bovax Biotechnology Co., Ltd.·Phase 3·NCT05027776·1,348 enrolled
A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia
Not yet recruiting·IInternational Agency for Research on Cancer·Phase 4·NCT07256912·1,266 enrolled
Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL
Completed·UUniversity of Witwatersrand, South Africa·Phase 2·NCT01928225·180 enrolled
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT00635830·40 enrolled
Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT01461096·575 enrolled
Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response
Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03296397·300 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)